Navigation Links
Isis Pharmaceuticals Announces Its Participation at the Upcoming,ACC 56th Annual Scientific Session in New Orleans and Its Live,Analyst/Investor Webcast Presentation

CARLSBAD, Calif., March 22, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals announces that results from three Phase 2 studies of ISIS 301012, including effects of ISIS 301012 in homozygous familial hypercholesterolemic (HoFH) patients, will be the subjects of three upcoming presentations at the of Cardiology (ACC), March 24-27 in New Orleans. Planned presentations include effects of ISIS 301012 in patients both as monotherapy and added to stable statin therapy. An overall summary of the Phase 2 program results for ISIS 301012 will be provided at the March 27 Analyst/Investor webcast presentation, along with a summary of Isis' development plan for ISIS 301012. ISIS 301012 is the Company's cholesterol-lowering drug targeting apoB-100.

    Sunday, March 25, 2007

    Session:          1206:  Vascular Disease, Hypertension and Prevention --

                      V-cast Poster

    Track:            ACC.Vascular Disease, Hypertension, and Prevention

    Room:             Hall H

    Presentation:     1206-278

    Abstract:         Statin-Like, Dose-Dependent Reductions in LDL-C and

                      Apolipoprotein B With ISIS 301012, an Antisense

                      Inhibitor of Apolipoprotein B, in Subjects With

                      Polygenic Hypercholesterolemia

    Monday, March 26, 2007

    Session:          603:  Common Challenges in Preventive Cardiology

                      (7:00 - 8:30 a.m. CT)

    Track:            ACC.Symposium

    Room:             Auditorium B

    Presentation:     603-8

    Time:             8:15 - 8:30 a.m.

    Speaker:          Dr. Evan A. Stein

    Title:            High Low-Density Lipoprotein Cholesterol on Three Drugs*

                      *to include preliminary results of an ongoing study

                      evaluating ISIS 301012 in HoFH patients on concurrent

                      maximally tolerated lipid-lowering therapies

    Session:          820:  Clinical Trials of 
Lipid-Lowering Therapy

                      (4:00 - 5:30 p.m. CT)

    Track:            ACC.Vascular Disease, Hypertension, and Prevention

    Room:             Auditorium B

    Presentation:     820-6

    Time:             4:45 - 5:00 p.m.

    Speaker:          Dr. John J.P. Kastelein

    Title:            ISIS 301012, an Antisense Inhibitor of Apolipoprotein B,

                      Produces Significant Additional Reduction of Low-Density

                      Lipoprotein Cholesterol and Apolipoprotein B in

                      Hypercholesterolemic Subjects on Statins Not Meeting


    Tuesday, March 27, 2007

    Presentation:     Isis Pharmaceuticals' Live Analyst/Investor Webcast

    Time:             7:00 a.m. CT


    How:              Live over the Internet -- select the link on Isis' home

                      page at the address above.

If you are unable to participate during the live webcast, the presentation will be available for replay at


Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 17 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing drugs for cancer, and inflammatory and other diseases. Ibis Biosciences, Inc., Isis' wholly owned subsidiary, is developing and commercializing the Ibis T5000 Biosensor System, a revolutionary system to identify infectious organisms. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of ov er 1,500 issued patents worldwide. Additional information about Isis is available at

This press release includes forward-looking statements regarding the development, therapeutic potential and safety of ISIS 301012 in treating high cholesterol and cardiovascular disease. Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement, including those statements that are described as Isis' goals or projections. Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, in developing and commercializing systems to identify infectious organisms that are effective and commercially attractive, and in the endeavor of building a business around such products. Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2006, which is on file with the SEC. Copies of this and other documents are available from the Company.

CONTACT: Kate Corcoran, Ph.D., Vice President, Corporate Development ofIsis Pharmaceuticals, +1- -760-603-2331

Web site:

Ticker Symbol: (NASDAQ-NM S:ISIS)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  Thanks to a donor with ... Mary,s Medical Center,s Sister Diane Grassilli Center for Women,s ... in San Francisco . ... stepped forward with a gift of $617,320 that allowed ... Mammography with Tomosynthesis and Whole Breast Ultrasound. Tomosynthesis, three-dimensional ...
(Date:11/24/2015)... CHAPEL HILL, N.C. , Nov. 24, 2015 /PRNewswire/ ... market research projects in an effort to quickly uncover ... market position. --> --> ... expeditiously launch a market research project and ensure that ... with company and industry standards. Another major barrier to ...
(Date:11/24/2015)... COMMACK, New York , 24. November ... Hersteller des Avery Breathing Pacemaker Systems, ist ... Ph.D., als Clinical Consultant bekannt geben zu ... -->   --> ... Stockholm (Schweden). Von 1984-1986 ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... Wimbledon Health Partners, ... new Wimbledon Athletics Facebook page to educate the public, parents and ... abnormalities. About 2,000 people under the age of 25 die from sudden cardiac ...
(Date:11/25/2015)... ... ... On November 23rd 2015 Cozy Products, a division of Bird-X Incorporated, ... explains what this means for business moving forward. , The Tri Lite heater business ... to sell personal heaters that reduce energy consumption, are economical and keep people warm ...
(Date:11/25/2015)... ... , ... SCOTTSDALE, AZ) - Today, Dr. Todd C. ... and non-surgical treatments, announced the expansion of his private practice capabilities with the ... Highly trained and nationally recognized for his natural approach, Dr. Todd Hobgood serves ...
(Date:11/25/2015)... ... November 25, 2015 , ... Brillianteen, McGaw YMCA’s student-produced ... in its 65th Anniversary Brillianteen Revue, scheduled for March 4-6, 2016. Auditions for ... years, Brillianteen has been a treasured tradition for numerous families in the Evanston ...
(Date:11/25/2015)... ... , ... “While riding the bus, I saw a passenger in a wheelchair ... to be a convenient and comfortable way to protect them from bad weather, so ... safely travel during cold or inclement weather. In doing so, it ensures that the ...
Breaking Medicine News(10 mins):